A process for producing injection-grade shell oligomers with extremely low protein residue

By pretreatment with room temperature NaOH solution, enzymatic hydrolysis with non-exogenous endochitosanase, high-speed centrifugation, and fractional micro/nano membrane separation, the problems of high protein residue and molecular weight control in the preparation of shell oligomers have been solved, realizing the production of injection-grade shell oligomers with extremely low protein residue and precise molecular weight, which is suitable for the biopharmaceutical field.

CN123063483APending Publication Date: 2026-11-10JIANGXI NORMAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611560712.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-10
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing processes for preparing shell oligomers result in high levels of residual protein, failing to meet injection-grade standards. High-temperature and strong-alkali conditions during raw material pretreatment damage the molecular structure, and large-particle impurities in the enzymatic hydrolysate cause membrane blockage and low enzyme-protein retention efficiency. Membrane separation processes struggle to simultaneously achieve trace protein removal and precise molecular weight control.

Method used

The process involves room temperature NaOH solution pretreatment, enzymatic hydrolysis with non-exogenous endo-chitosanase, high-speed centrifugation for impurity removal, and fractional micro/nano membrane separation. This process includes a combination of microfiltration, ultrafiltration, and nanofiltration membranes to remove large particulate impurities and precisely control molecular weight.

Benefits of technology

It effectively removes trace protein residues from products, has a precisely controllable molecular weight range, and extremely narrow dispersion, meeting the safety and bioactivity requirements of injection-grade shell oligomers, making it suitable for large-scale industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123063483A_ABST
    Figure CN123063483A_ABST
Patent Text Reader

Abstract

This invention relates to a production process for injection-grade chitosan oligomers with extremely low protein residue, belonging to the field of biomass medical functional materials technology. This invention breaks through traditional production methods, comprehensively employing effective raw material pretreatment technology, chitosanase-controlled degradation technology, initial high-speed centrifugation enzymatic hydrolysis technology, and alternating precise interception / removal of protein impurities using micro / nano membranes. Through the synergistic effect of multiple processes, the technical challenges of the irregularity of the disordered entanglement of fibrous high-molecular-weight chitosan polymers and the extreme difficulty in removing trace amounts of protein are effectively solved. The product's purity, uniformity, viscosity, and molecular weight range meet the quality standards for clinically applicable injection-grade chitosan oligomers. In particular, the extremely low protein residue (≤10 μg / mL) significantly improves the safety for in vivo application. Injectable chitosan oligomers, including injection-grade chitosan oligosaccharides, are urgently needed functional materials for gene delivery vectors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomass medical functional materials technology, and in particular to a production process for injection-grade shell oligomers with extremely low protein residue. Background Technology

[0002] Chitosan oligomers (i.e., low molecular weight chitosan) molecular weight chitosan, LMW Chitosan (CS) is a short-chain polymer derived from the degradation of natural high-molecular-weight chitosan raw materials, with a degree of polymerization (DP) of approximately 300 and a molecular weight (MW) of less than 50 kDa.

[0003] Chitosan oligosaccharides (COS) are oligomers containing chitosan oligosaccharides. Chitosan oligosaccharides are defined as oligomers with a degree of polymerization (DP) of 2 to 10 and a molecular weight (MW) of < 2 kDa.

[0004] Chitosan oligomers possess excellent properties such as good water solubility, high biocompatibility, and biodegradability, showing broad application prospects in biomedical fields such as gene delivery, tissue engineering, wound healing, and drug delivery. Particularly in the field of cell and gene therapy, chitosan nanoparticles, as non-viral gene carriers, have attracted significant attention due to their low toxicity and functionalizability in cutting-edge areas such as mRNA vaccines, siRNA therapy, CRISPR gene editing, and mucosal drug delivery.

[0005] However, the clinical translation of shell oligomers faces significant quality bottlenecks. Injectable shell oligomers have extremely stringent safety requirements, with protein residue being one of the most critical control indicators. Protein residue can trigger immunogenic reactions, allergic reactions, and even serious adverse events, representing a core obstacle preventing shell oligomers from transitioning from topical medical devices to in vivo injectable applications.

[0006] Injectable-grade chitosan oligosaccharides and injectable-grade shell oligomers are urgently needed functional materials in the biopharmaceutical field. Currently, the preparation of shell oligomers mainly includes the following methods: 1. Acid hydrolysis methods: including classic hydrochloric acid degradation, peracetic acid degradation, concentrated sulfuric acid degradation, hydrofluoric acid degradation, etc.; 2. Oxidative degradation methods: Represented by the hydrogen peroxide oxidation method, these mainly include the H2O2 method, H2O2-HCl method, H2O2-NaOCl2 method, ClO2 method, etc.

[0007] These traditional methods have the following inherent drawbacks: the molecular weight range of the product is uncontrollable, the dispersion is too wide, and the molecular size is uneven; in addition, the process consistency is poor, and batches cannot be repeated; the chemical reagent residues and protein impurities introduced during the degradation process are difficult to remove, and the products are only suitable for three types of external medical devices such as hemostasis and wound dressings.

[0008] In recent years, enzymatic degradation has gradually attracted attention due to its advantages such as mild reaction conditions and good molecular weight control. However, existing enzymatic processes still have the following problems: First, the raw material pretreatment generally adopts the traditional process of high-temperature treatment at 80℃ for 2 hours with 8% NaOH. Although the high temperature and strong alkaline conditions can remove proteins, they will severely damage the linear molecular structure of chitosan, leading to abnormal changes in the degree of deacetylation and molecular chain breakage, which in turn affects the efficiency of subsequent enzymatic hydrolysis and the bioactivity of the product. Second, the enzymatic hydrolysate contains large particulate impurities such as polysaccharide flocculants and residual suspended matter. Direct entry into the membrane separation system will cause irreversible membrane pore blockage, resulting in rapid decline in membrane flux and poor batch-to-batch membrane flux repeatability. At the same time, the retained enzyme protein will form a concentration polarization layer on the membrane surface, reducing the actual retention efficiency of the membrane for soluble proteases. Third, existing membrane separation processes mostly use a single ultrafiltration or nanofiltration step, which makes it difficult to simultaneously achieve trace protein removal and precise molecular weight control. The protein residue in the product is usually in the range of 0.1% to 0.5%, which is far from meeting the requirements for injection grade.

[0009] Low molecular weight chitosan (MW < 5kDa) is extremely difficult to refine, and the product quality requirements are stringent: precise controllable molecular weight range, narrow dispersibility, and low viscosity. In particular, safety indicators are even more stringent: extremely low protein residue, extremely low heavy metal contamination, and extremely low endotoxins.

[0010] Therefore, breaking through the technical bottleneck and developing a process that can stably produce injection-grade shell oligomers with extremely low protein residue has significant industrial value and strategic importance. Summary of the Invention

[0011] The technical problem to be solved by this invention is that: existing chitosan oligomer preparation processes result in high protein residue (usually ≥0.1%), which cannot meet the injection grade standard; the high temperature and strong alkaline conditions in the raw material pretreatment damage the chitosan molecular structure; large particulate impurities in the enzymatic hydrolysate cause membrane blockage and low enzyme protein retention efficiency; and membrane separation processes cannot simultaneously achieve trace protein removal and precise molecular weight control.

[0012] Therefore, this invention provides a production process for injection-grade shell oligomers with extremely low protein residue. The "production process for injection-grade shell oligomers with extremely low protein residue" provided by this invention can effectively remove trace amounts of protein from the product.

[0013] To achieve the above objectives, the present invention provides two specific research contents.

[0014] First, the present invention provides a process for producing injection-grade shell oligomers with extremely low protein residue, comprising the following steps: (1) Raw material pretreatment: After crushing and sieving the chitosan raw material, soak it in a 6%~10% NaOH solution at room temperature for 40min~80min. After solid-liquid separation, wash it with water (purified water PW, general grade for auxiliary material production) until neutral to obtain pretreated chitosan. (2) Enzymatic hydrolysis: The pretreated chitosan was dissolved in acetic acid buffer, and a specific endochitosanase without exolytic activity was added. The ratio of chitosan raw material mass to enzyme activity was 1:1~1:3 g / U. The enzymatic hydrolysis reaction was carried out at pH 5.0~6.0 and temperature 55℃~65℃ until the preset endpoint was reached to obtain the enzymatic hydrolysate. (3) High-speed centrifugation to remove impurities: Centrifuge the enzyme hydrolysate at 8000 rpm to 12000 rpm to remove large particles and flocculated aggregates, and collect the supernatant; (4) Separation by micro- and nano-membrane fractionation: The supernatant is sequentially passed through a microfiltration membrane, an ultrafiltration membrane, and a nanofiltration membrane for fractional separation. The microfiltration membrane has a pore size of 0.1 μm to 1 μm, the ultrafiltration membrane has a molecular weight cutoff of 3 kDa to 50 kDa, and the nanofiltration membrane has a molecular weight cutoff of 200 Da to 2 kDa. Finally, the nanofiltration retentate is collected to obtain a concentrated solution of separated and purified shell oligomers. (5) Freeze-drying: Freeze-dry the concentrated shell oligomer solution to obtain extremely low protein residue injection-grade shell oligomers with a protein residue of <100μg / mL (i.e. <0.01%).

[0015] Further, in step (1), the NaOH solution has a mass fraction of 8%; the soaking time at room temperature is 60 min; and the chitosan raw material is pulverized and passed through a 100-mesh standard sieve.

[0016] Further, in step (2), the specific endoglucanase without exonuclease activity is a recombinant chitosanase expressed by Pichia pastoris with zero exonuclease activity; or a commercial specific chitosanase, general CAS number: 51570-20-8 (GMP pharmaceutical grade).

[0017] Further, in step (2), the ratio of chitosan raw material mass to enzyme activity is 1:1 to 1:3 g / U; the preset endpoint is when the viscosity of the reaction solution drops to 0.7 to 2 mPa.s (set according to the requirements of the customized target product), that is, the enzymatic hydrolysis reaction is stopped.

[0018] Furthermore, in step (3), the centrifugation speed is 10,000 rpm and the centrifugation time is 10 min.

[0019] Further, in step (4), the graded separation sequentially uses micro-nano membranes such as 0.22μm microfiltration membrane, 0.1μm microfiltration membrane, 20kDa or 10kDa ultrafiltration membrane, and 2kDa or 1kDa nanofiltration membrane.

[0020] Furthermore, in step (4), a suitable combination of ultrafiltration and nanofiltration membrane pore sizes is selected according to the molecular weight range requirements of the target product, so that the weight-average molecular weight distribution of the resulting shell oligomers is within the range of 300 Da to 50 kDa, and the dispersion PDI is ≤ 1.5. Even further, the weight-average molecular weight range is precisely controllable, and while the dispersion is extremely narrow, endotoxins are effectively retained and residual proteins are removed, achieving the quality requirements for injection-grade shell oligomers.

[0021] Second, the present invention provides an injection-grade shell oligomer, which is prepared by the production process described in the present invention.

[0022] Furthermore, the obtained injection-grade shell oligomers include injection-grade shell oligomers with a weight-average molecular weight (3 kDa ~ 50 kDa) and a dispersion PDI ≤ 1.5; they also include chitosan oligosaccharides with a weight-average molecular weight (≤ 2 kDa) and a degree of polymerization (DP) of 2 ~ 8 and a dispersion PDI ≤ 1.2. All meet the physicochemical standards for clinical gene vectors in the biomedical field.

[0023] Furthermore, the resulting injectable shell oligomers have a protein residue of ≤10 μg / mL, an endotoxin content of ≤0.025 EU / mg, and a heavy metal content of ≤5 ppm. This meets the biosafety standards for clinically used gene vectors in the biopharmaceutical field.

[0024] Compared with the injection-grade shell oligomers obtained by the prior art, the present invention has at least the following significant advantages: 1. This invention employs a four-step synergistic protein removal mechanism: "room temperature alkaline solution pretreatment to remove raw material-bound proteins → non-exoclastically active specific enzymatic hydrolysis to reduce the introduction of contaminating proteins → high-speed centrifugation to remove flocculent protein aggregates → hierarchical micro / nano membrane to retain soluble proteins." This mechanism stably controls the residual protein content of the final product to <10 μg / mL, which is far lower than the existing pharmaceutical-grade chitosan standard (≤0.2%), meeting the requirements for injectable applications and greatly improving the safety of in vivo applications.

[0025] 2. This invention overcomes the technical limitations of traditional high-temperature treatment at 80°C for 2 hours with 8% NaOH, employing a milder condition of 1 hour at room temperature with 8% NaOH. Experiments have shown that under these conditions, protein impurities are thoroughly removed without damaging the linear molecular structure of chitosan, maintaining stable deacetylation degree and molecular weight distribution, and unaffected in vitro cell transfection efficiency. In contrast, traditional high-temperature conditions lead to chitosan molecular chain breakage and abnormal fluctuations in deacetylation degree, severely impacting the product's bioactivity.

[0026] 3. This invention incorporates a high-speed centrifugation step of 10,000 rpm before membrane separation, effectively removing large particulate impurities such as polysaccharide flocs and residual suspended matter from the enzymatic hydrolysate, thus reducing the colloidal content of the hydrolysate. This design fundamentally solves the problem of irreversible membrane pore blockage caused by large particulate impurities, significantly improving the retention stability of micro / nanofiltration membranes for soluble proteases, and enhancing batch-to-batch membrane flux repeatability compared to traditional processes.

[0027] 4. This invention employs a multi-stage membrane separation combination of 0.22μm and 0.1μm microfiltration → 20kDa / 10kDa ultrafiltration → 2kDa / 1kDa nanofiltration. Microfiltration removes residual particles and colloids, ultrafiltration precisely controls the molecular weight range of the target shell oligomers, and nanofiltration achieves concentration while precisely controlling the molecular weight range of the target shell oligomers. This fractionation system efficiently removes trace amounts of soluble proteins while stably producing shell oligomer products with extremely narrow dispersion and precisely controllable molecular weight range. Furthermore, the membrane pore size combination can be flexibly selected to customize products with specific molecular weight ranges according to user needs.

[0028] 5. This invention employs a specific endochitosanase without exonuclease activity, avoiding the problem of exonucleases progressively hydrolyzing from the non-reducing end to produce monosaccharides (glucosamine). Testing revealed no monosaccharide components in the enzymatic hydrolysis products. This significantly increases the yield of the target product.

[0029] 6. The process of this invention is simple, with clearly defined and controllable parameters for each step, good batch-to-batch repeatability, and a product yield of ≥75%. It has completed kilogram-level pilot production and can be directly scaled up to industrial-grade reactors and membrane separation systems, making it suitable for large-scale industrial production. The resulting product has excellent flowability, making it particularly suitable for the mass production of chitosan nanoparticles using microfluidic equipment, providing a reliable raw material guarantee for the clinical application of chitosan oligomers in injectable biopharmaceuticals. Attached Figure Description

[0030] To more clearly illustrate the specific solutions in the embodiments of this application or the prior art, the accompanying drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the accompanying drawings described below are merely product quality analysis diagrams of two specific embodiments recorded in this application.

[0031] For those skilled in the art, other figures can be obtained from these figures without any creative effort.

[0032] Figure 1 This is a product quality analysis chart (MW1886Da, PDI:1.10) from Example 1 of a preferred embodiment of the present invention. Figure 2 This is a product quality analysis chart (GPC calibration curve standard) of Example 1 in a preferred embodiment of the present invention. Figure 3 This is a product quality analysis chart (MW3895Da, PDI:1.33) from Example 2 of a preferred embodiment of the present invention. Figure 4 This is a product quality analysis chart (GPC calibration curve standard) of Example 2 in a preferred embodiment of the present invention. Figure 5 This is a product quality analysis chart (MW11561Da, PDI: 1.47) from Example 3 of a preferred embodiment of the present invention. Figure 6 This is a product quality analysis chart (GPC calibration curve standard) of Example 3 in a preferred embodiment of the present invention. Figure 7 This is a product quality analysis chart (MW48020Da, PDI: 1.38) from Example 4 of a preferred embodiment of the present invention. Figure 8 This is a product quality analysis chart (GPC calibration curve standard) of Example 4 in a preferred embodiment of the present invention. Figure 9 This is a product quality analysis chart (MW75878Da, PDI: 1.79) for Comparative Example 5, a preferred embodiment of the present invention. Figure 10 This is a product quality analysis chart (GPC calibration curve standard) of Comparative Example 5 in a preferred embodiment of the present invention. Detailed Implementation

[0033] The endpoints and any values ​​of the ranges disclosed herein are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of the various ranges, the endpoint values ​​of the various ranges and individual point values, and individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed herein.

[0034] In this invention, the ambient temperature generally refers to 20℃~30℃. In special cases, it may be slightly lower (e.g., 15℃) or slightly higher (e.g., 35℃). Only the soaking treatment time of this invention needs to be adjusted, without affecting the technical effect of this invention.

[0035] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some, not all, of the embodiments of the present invention. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are within the scope of protection of the present invention.

[0036] The raw materials used in the following embodiments are all publicly available in the prior art and can be purchased directly.

[0037] Example 1: Preparation of injection-grade chitosan oligosaccharide (MW≤2kDa) 1. Selection of main raw materials (1) Chitosan raw material selection criteria: Deacetylation degree ≥ 92%, and heavy metal content should meet the standards of Chinese Pharmacopoeia and United States Pharmacopoeia.

[0038] (2) Selection criteria for commercially available specific chitosanase: General CAS No.: 51570-20-8 (GMP pharmaceutical grade) 2. Raw material pretreatment Take 1000g of chitosan raw material (92% degree of deacetylation), pulverize it, and pass it through a 100-mesh standard sieve to remove large agglomerated particles. Soak the chitosan raw material powder in 8% NaOH alkaline solution (1 kg raw material: 15 L alkaline solution) at room temperature, stirring slowly for 60 min, and then filter to remove water. Wash with purified water (PW, general grade for auxiliary material production) until the pH is neutral (pH 7.0±0.2), and then filter to remove water again to obtain pretreated chitosan.

[0039] 3. Prepare an acetic acid solution (pH 5.0~5.5) containing 3% chitosan raw material. (1) Add 18 L of purified water to a 100 L reactor (stainless steel).

[0040] (2) Slowly add the pretreated chitosan into the reactor.

[0041] (3) Turn on the stirring device, set the stirring speed to 70 rpm, and start the heating function at the same time, setting the temperature to 60℃.

[0042] (4) After heating the solution for 30 minutes, add 15 L of 2% (V / V) acetic acid aqueous solution and measure the pH value to reach 5.0~5.5.

[0043] (5) Continue stirring and heating until the temperature of the chitosan acetic acid solution stabilizes at 60°C, ensuring that the chitosan is evenly dispersed and forming a 3% chitosan dilute colloidal solution.

[0044] 4. Enzymatic hydrolysis and cooling (1) Prepare 0.1L aqueous solution of 2000 U endochitosanase according to the ratio of chitosan raw material mass to enzyme activity of 1:2 g / U, and add it evenly to the reaction vessel.

[0045] (2) Continue stirring at a constant temperature to ensure that the enzyme and chitosan solution are fully mixed and in uniform contact, and the enzymatic reaction continues. Terminate the enzymatic reaction when the viscosity of the reaction solution reaches the preset value of 0.7 mPa·s. Turn off the heating and stirring, remove the container, and cool to 25°C.

[0046] 5. High-speed centrifugation to remove impurities: Centrifuge the enzyme hydrolysate cooled to 25°C at an initial high speed of 10,000 rpm for 10 minutes to remove large particulate impurities and flocculent aggregates, and collect the supernatant. 6. Hierarchical micro / nano membrane separation: According to product customization requirements, injection-grade chitosan oligosaccharides (MW≤2kDa) are sequentially separated using the following micro / nano membrane modules: (1) 0.22μm microfiltration membrane: removes residual particles and colloidal impurities and collects the permeate; (2) 0.1μm microfiltration membrane: further removes submicron particles and collects the permeate; (3) 10kDa ultrafiltration membrane: further retains medium-molecular-weight protein and polysaccharide fragments, and collects the permeate; (4) 1kDa nanofiltration membrane: Further concentration was achieved using a 1kDa nanofiltration membrane, and the retentate was collected to obtain a shell oligomer liquid with a molecular weight range of 1000Da~2000Da, which was then concentrated to a solid content of about 20%.

[0047] 7. The purified and concentrated enzymatic hydrolysate was freeze-dried to obtain 783 g of white, loose, powdery injection-grade chitosan oligosaccharide, with a yield ≥75%. The product chitosan oligosaccharide has a weight-average molecular weight (MW) of 1886 Da and low dispersibility (PDI 1.1). Figure 1 , Figure 2 As shown.

[0048] The product quality test results of Example 1 are shown in Table 1 below. Table 1 Example 2: Preparation of injection-grade shell oligomers (molecular weight range 3kDa~50kDa) The difference between this embodiment and Example 1 lies in the different viscosity of the enzymatic hydrolysate at the time of reaction termination and the different combination of membrane separation pore sizes, as detailed below: 1. Raw material selection: Same as in Example 1.

[0049] 2. Raw material pretreatment: Same as in Example 1.

[0050] 3. Prepare an acetic acid solution (pH 5.0~5.5) of 3% chitosan raw material: Same as in Example 1.

[0051] 4. Enzymatic hydrolysis and cooling: The enzymatic reaction was terminated when the viscosity of the hydrolysate reached the preset value of 0.8 mPa·s, as monitored online. The rest was the same as in Example 1.

[0052] 5. High-speed centrifugation for impurity removal: Same as in Example 1.

[0053] 6. Separation by micro- and nano-membrane fractionation: The solution is sequentially passed through a 0.22 μm microfiltration membrane → a 0.1 μm microfiltration membrane → a 20 kDa ultrafiltration membrane → a 2 kDa nanofiltration membrane. The 2 kDa nanofiltration retentate is collected to obtain a shell oligomer liquid, which is then concentrated to a solid content of approximately 20%.

[0054] 7. Freeze-drying: The purified and concentrated enzymatic hydrolysate was freeze-dried to obtain 791g of white, loose, powdery injection-grade shell oligomers, with a yield ≥75%. The product shell oligomers have a weight-average molecular weight (MW 3895 Da) and low dispersibility (PDI 1.33). Figure 3 , Figure 4 As shown.

[0055] The product quality test results for Example 2 are shown in Table 2 below.

[0056] Table 2 Example 3: Preparation of injection-grade shell oligomers (molecular weight range 3kDa~50kDa) The difference between this embodiment and Example 1 lies in the different viscosity of the enzymatic hydrolysate at the time of reaction termination and the different combination of membrane separation pore sizes, as detailed below: 1. Raw material selection: Same as in Example 1.

[0057] 2. Raw material pretreatment: Same as in Example 1.

[0058] 3. Prepare an acetic acid solution (pH 5.0~5.5) of 3% chitosan raw material: Same as in Example 1.

[0059] 4. Enzymatic hydrolysis and cooling: The enzymatic reaction was terminated when the viscosity of the hydrolysate reached the preset value of 1.2 mPa·s, as monitored online. The rest was the same as in Example 1.

[0060] 5. High-speed centrifugation for impurity removal: Same as in Example 1.

[0061] 6. Separation by micro- and nano-membrane fractionation: The solution is sequentially passed through a 0.22 μm microfiltration membrane → a 0.1 μm microfiltration membrane → a 20 kDa ultrafiltration membrane → a 2 kDa nanofiltration membrane. The 2 kDa nanofiltration retentate is collected to obtain a shell oligomer liquid, which is then concentrated to a solid content of approximately 20%.

[0062] 7. Freeze-drying: The purified and concentrated enzymatic hydrolysate was freeze-dried to obtain 766g of white, loose, powdery injection-grade shell oligomers, with a yield ≥75%. The product shell oligomers have a weight-average molecular weight (MW 11561 Da) and low dispersibility (PDI 1.47). Figure 5 , Figure 6 As shown.

[0063] The product quality test results of Example 3 are shown in Table 3 below.

[0064] Table 3 Example 4: Preparation of injection-grade shell oligomers (molecular weight range 3kDa~50kDa) The difference between this embodiment and Example 1 lies in the different viscosity of the enzymatic hydrolysate at the time of reaction termination and the different combination of membrane separation pore sizes, as detailed below: 1. Raw material selection: Same as in Example 1.

[0065] 2. Raw material pretreatment: Same as in Example 1.

[0066] 3. Prepare an acetic acid solution (pH 5.0~5.5) of 3% chitosan raw material: Same as in Example 1.

[0067] 4. Enzymatic hydrolysis and cooling: The enzymatic reaction was terminated when the viscosity of the hydrolysate reached the preset value of 2.0 mPa·s, as monitored online. The rest was the same as in Example 1.

[0068] 5. High-speed centrifugation for impurity removal: Same as in Example 1.

[0069] 6. Separation by micro- and nano-membrane fractionation: The solution is sequentially passed through a 0.22 μm microfiltration membrane → a 0.1 μm microfiltration membrane → a 20 kDa ultrafiltration membrane → a 2 kDa nanofiltration membrane. The 2 kDa nanofiltration retentate is collected to obtain a shell oligomer liquid, which is then concentrated to a solid content of approximately 20%.

[0070] 7. Freeze-drying: The purified and concentrated enzymatic hydrolysate was freeze-dried to obtain 757g of white, loose, powdery injection-grade shell oligomers, with a yield ≥75%. The product shell oligomers have a weight-average molecular weight (MW 48020 Da) and low dispersibility (PDI 1.38). Figure 7 , Figure 8 As shown.

[0071] The product quality test results of Example 4 are shown in Table 4 below.

[0072] Table 4 The results showed that: ① Controlling the molecular weight range of shell oligomers based on changes in the viscosity of the enzymatic hydrolysis solution was highly sensitive. An increase of only 0.1 mPa·s in viscosity increased the weight-average molecular weight of the product from 1886 Da to 3895 Da (>2 kDa). Simultaneously, coupled micro / nano membrane filtration effectively removed protein residues and synergistically and precisely controlled the molecular weight range. ② As the viscosity of the enzymatic hydrolysis solution continued to increase by 0.5 mPa·s (reaching 1.2 mPa·s), the weight-average molecular weight of the product increased to 11561 Da. The increase in molecular weight range was directly proportional to the increase in viscosity.

[0073] Repeated experiments verified that the enzyme hydrolysate viscosity of 0.7 mPa·s reached the reaction endpoint. Coupling enzyme hydrolysates of different viscosities with corresponding micro / nano membrane combinations can effectively remove protein residues and synergistically and precisely control the molecular weight range.

[0074] Therefore, by detecting the changes in viscosity of the enzymatic hydrolysis solution online, the degree of enzymatic hydrolysis can be controlled in a timely manner, thereby accurately controlling the molecular weight range of the shell oligomer product. This effectively solves the technical problem of the strict requirements for the high stability and repeatability of the molecular weight range between batches of injection-grade shell oligomer products, breaking through this technical bottleneck that has long plagued the quality control of mass production for enterprises.

[0075] Example 5: Alkali pretreatment process with 6% NaOH concentration (less than 8% NaOH) The only difference between this embodiment and Embodiment 1 is that the raw material pretreatment step uses an alkaline solution treatment process with a concentration of less than 8% NaOH: the chitosan raw material powder is soaked in 6% NaOH alkaline solution, and the remaining steps are the same as in Embodiment 1.

[0076] The test results are shown in Table 5 below: Table 5 Example 6: Alkali pretreatment process with 10% NaOH concentration (greater than 8% NaOH) The only difference between this embodiment and Embodiment 1 is that the raw material pretreatment step uses an alkaline solution with a concentration higher than 8% NaOH: the chitosan raw material powder is soaked in 10% NaOH alkaline solution, and the remaining steps are the same as in Embodiment 1.

[0077] The test results are shown in Table 6 below: Table 6 The results showed that: ① Alkaline pretreatment with a concentration below 8% NaOH (6% NaOH) effectively removed residual protein, but not completely. It had no effect on the chitosan molecular structure or subsequent cell transfection performance (see results in Example 5). ② Alkaline pretreatment with a concentration above 8% NaOH (10% NaOH) effectively removed residual protein. However, high concentrations of alkali began to affect the chitosan molecular structure and subsequent cell transfection performance (see results in Example 6).

[0078] In Example 1, treatment with an 8% alkaline solution at room temperature effectively removed protein impurities adhering to the raw materials while saving energy and time. More importantly, it protected the structural stability of the biofunctional materials while efficiently removing protein residues.

[0079] Comparative Example 1: Traditional High-Temperature Alkali Pretreatment Process The only difference between this comparative example and Example 1 is that the raw material pretreatment step adopts a traditional process: 8% NaOH solution, high temperature treatment at 80°C for 2 hours, and the other steps are the same as in Example 1.

[0080] The test results are shown in Table 7 below: Table 7 The results showed that while traditional high-temperature (80℃) alkaline pretreatment for protein residues was effective, it was not thorough. This is because high temperatures significantly strengthen the hydrogen bonds between chitosan molecules, causing the molecular chains to aggregate tightly and form a dense solid phase. This phase encapsulates the internal bound proteins, effectively "locking" proteins and other impurities within the particles, making them difficult to diffuse outwards and remove. Only surface-free proteins can be eluted. Furthermore, the longer the treatment time, the more the high temperature causes particle aggregation, making subsequent permeation and washing more difficult. On the other hand, high temperatures can damage the chitosan molecular structure, leading to changes in the degree of deacetylation and altering the amino group number. These changes in the N / P ratio negatively impact subsequent in vitro cell transfection performance, failing to meet the functional requirements of gene vectors.

[0081] The room temperature, dilute alkali treatment in Example 1 not only efficiently removes protein impurities adhering to the raw materials but also saves energy and time. More importantly, it protects the structural stability of the biofunctional materials while efficiently removing protein residues.

[0082] Comparative Example 2: Alkali Pretreatment Process at 40℃ (Above Normal Temperature) The only difference between this comparative example and Example 1 is the raw material pretreatment step: 8% NaOH solution, 40°C soaking treatment. The other steps are the same as in Example 1.

[0083] The test results are shown in Table 8 below: Table 8 Comparative Example 3: Alkali Pretreatment Process at 60℃ (Above Normal Temperature) The only difference between this comparative example and Example 1 is the raw material pretreatment step: 8% NaOH solution, 60°C treatment for 2 hours. The remaining steps are the same as in Example 1.

[0084] The test results are shown in Table 9 below: Table 9 The results showed that when pretreatment with dilute alkali at temperatures above room temperature, the effect of removing protein residues did not improve with increasing temperature, and the damage to the chitosan molecular structure gradually increased (see Comparative Examples 2 and 3).

[0085] Comparative Example 4: Alkali pretreatment process with 12% NaOH concentration (greater than 10% NaOH) The only difference between this comparative example and Example 1 is that the raw material pretreatment step uses an alkaline solution with a concentration higher than 10% NaOH: the chitosan raw material powder is soaked in 12% NaOH alkaline solution, and the remaining steps are the same as in Example 1.

[0086] The test results are shown in Table 10 below: Table 10 The results showed that pretreatment with alkali solutions higher than 10% (12% NaOH) was very effective in removing protein residues. However, high concentrations of alkali solution began to affect the chitosan molecular structure and subsequent cell transfection performance.

[0087] In Example 1, treatment with an 8% alkaline solution at room temperature effectively removed protein impurities adhering to the raw materials while saving energy and time. More importantly, it protected the structural stability of the biofunctional materials while efficiently removing protein residues.

[0088] Comparative Example 5: Production process in which the reaction is terminated when the viscosity of the enzymatic hydrolysate is predetermined to be 2.5 mPa·s. The only difference between this comparative example and Example 1 is that the viscosity of the enzymatic hydrolysate at the end of the reaction continues to increase to 2.5 mPa·s; the other steps are the same as in Example 1.

[0089] 673 g of white, loose, lyophilized chitosan was obtained, with a yield of <70%. The product's shell oligomers have a weight-average molecular weight (MW 75878 Da) and high dispersibility (PDI 1.79). Figure 9 , Figure 10 As shown.

[0090] The test results are shown in Table 11 below: Table 11 The results showed that when the viscosity of the enzymatic hydrolysate exceeded 2.0 mPa·s, the molecular weight of the enzymatic hydrolysate increased significantly with increasing viscosity, exceeding the defined molecular weight range of shell oligomers (3 kDa-50 kDa), and the dispersibility was also >1.5. Such a product cannot be used as a gene delivery vector for in vivo cell and gene therapy. However, because its protein residue, endotoxin content, and heavy metal content all meet medical-grade standards, it can be used externally as a wound hemostatic dressing or as a tissue scaffold.

[0091] Comparative Example 6: Process without high-speed centrifugation step The only difference between this comparative example and Example 1 is that step 5, high-speed centrifugation to remove impurities, is omitted, and the enzymatic hydrolysate is directly introduced into the fractional micro / nano membrane separation system. The remaining steps are the same as in Example 1.

[0092] The test results are shown in Table 12 below: Table 12 The results show that for polypropylene microfiltration membranes, omitting the high-speed centrifugation step allows large particles and flocculants from the enzymatic hydrolysate to directly enter the membrane system, causing severe irreversible pore blockage. The concentration polarization layer formed on the membrane surface reduces the actual retention efficiency of the membrane for soluble proteins, increasing the residual protein content in the product and failing to meet injection-grade standards. Simultaneously, the adsorption of target products by large particles leads to a decrease in yield, and irreversible membrane blockage causes a gradual decline in flux recovery after washing, severely impacting the membrane module's lifespan. The damage is even greater for PES (polyethersulfone) spiral-wound ultrafiltration membranes that cannot be reverse-washed, resulting in shortened lifespan, increased production costs, and significant economic losses.

[0093] Comparative Example 7: Single Ultrafiltration Membrane Separation Process The only difference between this comparative example and Example 1 is that in step 6, only a single 10kDa ultrafiltration membrane is used for separation and purification, without fractional micro / nano membrane separation. The remaining steps are the same as in Example 1.

[0094] The results showed that the protein residue in Comparative Example 7 exceeded the standard, with a weight-average molecular weight ≥2kDa and a PDI ≥1.5. This indicates that a single ultrafiltration membrane cannot simultaneously achieve trace protein removal and precise molecular weight control; it only provides a concentration effect and cannot meet the stringent requirements for quality uniformity and extremely low protein contamination in injection-grade products.

[0095] Comparative Example 8: Conventional chitosanase (with exoglycosidic activity) process The only difference between this comparative example and Example 1 is that step 4 uses a common commercial chitosanase with exonuclease activity; the other steps are the same as in Example 1.

[0096] Test results: Although Comparative ratio 8 did not affect the removal of protein residues, the presence of a large amount of monosaccharides in the enzymatic hydrolysate (content ≥30%) significantly reduced the yield of the target product, injection-grade chitosan oligomers, with a production rate below 50%. Simultaneously, it increased the burden of removing a large amount of monosaccharide impurities during the process, severely reducing the purity and dispersibility of the target product. Therefore, it is crucial to select a high-purity chitosanase preparation for producing injection-grade chitosan oligomers; it is essential to purchase GMP-certified pharmaceutical-grade commercially available specific chitosanase.

[0097] Experimental conclusions Based on the experimental results of the above embodiments and comparative examples, the following conclusions can be drawn: (1) The four-step synergistic protein removal mechanism of the present invention (room temperature alkaline pretreatment → controllable degradation by a specific enzyme without exokinetic activity → high-speed centrifugation → fractional micro / nano membrane separation) can stably control the residual protein content of shell oligomers to ≤10μg / mL (i.e. ≤0.001%), which is superior to the current injectable grade standards implemented by various countries, ensuring safe clinical application. At the same time, it solves the problem of accurately controlling the molecular weight range of shell oligomers, ensuring the stable performance of injectable shell oligomer products.

[0098] (2) Room temperature alkaline pretreatment (8% NaOH, 25℃, 1h) effectively protects the integrity of chitosan molecular structure and maintains the bioactivity of the product while ensuring protein removal. It is also energy-saving and time-saving, significantly superior to traditional high-temperature strong alkaline processes. (3) The high-speed centrifugation pre-step is the key to ensuring the stable operation of the membrane separation system and the protein retention efficiency. Omitting this step will lead to severe membrane blockage, excessive protein residue, and poor batch repeatability. (4) The key technology of online detection of enzyme hydrolysate viscosity to control the degree of reaction is coupled with graded micro-nano membrane separation, which is the core to achieve the unity of trace protein removal and precise molecular weight control. Single membrane separation cannot meet the dual requirements of injection-grade products. (5) Using a specific endochitosanase without exo-glucanase activity can ensure a high conversion rate of the target shell oligomer product.

[0099] The above description is merely a preferred embodiment of the present invention, and the present invention is not limited to the above embodiments. It is understood that other improvements and variations that are directly derived or conceived by those skilled in the art without departing from the spirit and concept of the present invention should be considered to be included within the protection scope of the present invention.

Claims

1. A process for producing injection-grade shell oligomers with extremely low protein residue, characterized in that, Includes the following steps: (1) Raw material pretreatment: After crushing and sieving the chitosan raw material, soak it in a NaOH solution with a mass fraction of 6%~10% for 40min~80min at room temperature. After solid-liquid separation, wash it with water until neutral to obtain pretreated chitosan. (2) Enzymatic hydrolysis: The pretreated chitosan was dissolved in acetic acid buffer, and a specific endochitosanase without exolytic activity was added. The ratio of chitosan raw material mass to enzyme activity was 1:1~1:3 g / U. The enzymatic hydrolysis reaction was carried out at pH 5.0~6.0 and temperature 55℃~65℃ until the preset endpoint was reached to obtain the enzymatic hydrolysate. (3) High-speed centrifugation to remove impurities: Centrifuge the enzyme hydrolysate at 8000 rpm to 12000 rpm to remove large particles and flocculated aggregates, and collect the supernatant; (4) Separation by micro- and nano-membrane fractionation: The supernatant is sequentially passed through a microfiltration membrane, an ultrafiltration membrane, and a nanofiltration membrane for fractional separation. The microfiltration membrane has a pore size of 0.1 μm to 1 μm, the ultrafiltration membrane has a molecular weight cutoff of 3 kDa to 50 kDa, and the nanofiltration membrane has a molecular weight cutoff of 200 Da to 2 kDa. The nanofiltration retentate is collected to obtain a concentrated solution of separated and purified shell oligomers. (5) Freeze-drying: Freeze-dry the concentrated shell oligomer solution to obtain injection-grade shell oligomers with extremely low protein residue of <100μg / mL.

2. The production process according to claim 1, characterized in that, In step (1), the NaOH solution has a mass fraction of 8%; the soaking time at room temperature is 60 min; and the chitosan raw material is pulverized and passed through a 100-mesh standard sieve.

3. The production process according to claim 1, characterized in that, In step (2), the specific endoglucanase without exonuclease activity is a recombinant chitosanase expressed by Pichia pastoris, whose exonuclease activity is zero; or a commercial specific chitosanase, general CAS number: 51570-20-8, GMP pharmaceutical grade, is used.

4. The production process according to claim 1, characterized in that, In step (2), the ratio of chitosan raw material mass to enzyme activity is 1:1 to 1:3 g / U; the preset endpoint is when the viscosity of the reaction solution drops to 0.7 to 2 mPa.s, i.e., the enzymatic hydrolysis reaction is stopped.

5. The production process according to claim 1, characterized in that, In step (3), the centrifugation speed is 10,000 rpm at the beginning and the centrifugation time is 10 min.

6. The production process according to claim 1, characterized in that, In step (4), the fractionation separation sequentially uses micro-nano membranes such as 0.22μm microfiltration membrane, 0.1μm microfiltration membrane, 20kDa or 10kDa ultrafiltration membrane, and 2kDa or 1kDa nanofiltration membrane.

7. The production process according to claim 1, characterized in that, In step (4), according to the molecular weight range requirements of the target product, a suitable combination of ultrafiltration and nanofiltration membrane pore sizes is selected so that the weight average molecular weight distribution of the resulting injection-grade shell oligomer is in the range of 300 Da to 50 kDa and the dispersion PDI is ≤ 1.2 to 1.

5.

8. An injection-grade shell oligomer, characterized in that, It is prepared by the production process described in any one of claims 1-7.

9. The injection-grade shell oligomer according to claim 8, characterized in that, The weight-average molecular weight distribution of the obtained injection-grade shell oligomers is in the range of 300 Da to 50 kDa, and the dispersion PDI is ≤1.

5.

10. The injection-grade shell oligomer according to claim 8, characterized in that, The resulting injection-grade shell oligomers have a protein residue of ≤10μg / mL, an endotoxin content of ≤0.025EU / mg, and a heavy metal content of ≤5ppm.